HC Wainwright Reaffirms “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)

HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report published on Tuesday, Benzinga reports. The brokerage currently has a $80.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on CLDX. Cantor Fitzgerald restated an overweight rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. Guggenheim increased their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a buy rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $66.00.

Celldex Therapeutics Stock Up 1.3 %

Celldex Therapeutics stock opened at $42.21 on Tuesday. The company’s 50-day moving average price is $41.91 and its 200-day moving average price is $37.00. The company has a market cap of $2.36 billion, a PE ratio of -14.51 and a beta of 1.60. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The company had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $1.20 million. As a group, sell-side analysts expect that Celldex Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics in the 1st quarter worth $147,000. Swiss National Bank lifted its stake in Celldex Therapeutics by 17.8% in the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after acquiring an additional 17,300 shares during the period. Jennison Associates LLC grew its holdings in Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after acquiring an additional 668,002 shares in the last quarter. Capstone Investment Advisors LLC increased its position in Celldex Therapeutics by 50.7% during the 1st quarter. Capstone Investment Advisors LLC now owns 19,065 shares of the biopharmaceutical company’s stock valued at $800,000 after purchasing an additional 6,412 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Celldex Therapeutics by 10.0% in the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 1,194 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.